Clinical trial registry record

Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal

A registered study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Terminated.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated March 25, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04764656
Last registry update
March 25, 2025
Status
Terminated
Phase
Phase not reported
Sponsor
Novartis Pharmaceuticals
Enrollment
81
Countries
Portugal
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
OBSERVATIONAL
Evidence population
Human clinical study registration
Participants
81
Population
ALL · 40 Years to 110 Years
Duration
2021-05-10 to 2024-02-16
Intervention
Brolucizumab
Comparator
Not reported
Outcomes measured
Percentage of patients that are absent of subretinal fluid (SRF) and intra-retinal fluid (IRF) in the study eye — month…; Fluid resolution after initiation of brolucizumab — month 24; Visual Actuity (VA) change from baseline — Baseline, month 24; Characterize Choroidal Neovascularization (CNV) morphology (BIRL) and activity — month 24; Number of injections and total number of visits — month 24; Describe the distribution of injection intervals — month 24; Number of Spectral Contrast Optical Coherence Tomography (SC-OCTs) done — month 24; Characterize the patients switching to another antivascular endothelial growth factor (anti-VEGF) — month 24; Discontinuation rate — month 24; Assess the safety of brolucizumab — month 24
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains: age-related macular degeneration. Source terminology supplies longevity context: age-related. Study type is explicitly identified as OBSERVATIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON